Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study.

Carcinoma, Non-Small-Cell Lung / drug therapy Chemoradiotherapy Female Humans Lung Neoplasms / drug therapy Neoplasm Recurrence, Local / drug therapy Platinum / therapeutic use Retrospective Studies
Cytotoxic chemotherapy Platinum-based chemotherapy Second-line setting Single-agent chemotherapy Survival

Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
29 Mar 2022
Historique:
received: 13 05 2021
accepted: 15 03 2022
entrez: 30 3 2022
pubmed: 31 3 2022
medline: 5 4 2022
Statut: epublish

Résumé

Platinum-based chemoradiotherapy is the standard treatment for unresectable stage III non-small-cell lung cancer (NSCLC). However, few studies have evaluated the efficacy of subsequent chemotherapy for relapsed NSCLC following platinum-based chemoradiotherapy. This study aimed to evaluate the efficacy of platinum-doublet chemotherapy as a second-line treatment for patients with unresectable stage III NSCLC. We retrospectively evaluated patients with unresectable stage III NSCLC treated with cytotoxic chemotherapy following platinum-based chemoradiotherapy who were registered in a nationwide registry NSCLC database. Patients were divided into the platinum-doublet chemotherapy (platinum) group and single-agent chemotherapy (non-platinum) group based on the type of second-line chemotherapy. The platinum group (n = 119) showed significantly better overall survival (OS) than the non-platinum group (n = 201) (median OS: 21.5 vs. 10.5 months, hazard ratio [HR]: 0.54, 95% confidence interval [CI]: 0.40-0.73, p < 0.001). OS from the beginning of chemoradiotherapy was also significantly better in the platinum group than in the non-platinum group (median OS: 34.9 vs. 21.8 months, HR: 0.58, 95% CI: 0.43-0.79, p = 0.001). In the multivariate analysis, platinum-doublet chemotherapy as second-line therapy, female sex, clinical stage IIIA, and duration of ≥ 8.6 months from the beginning of first-line therapy to the beginning of second-line therapy were associated with significantly better OS. Platinum-doublet chemotherapy as a second-line therapy may prolong survival in unresectable stage III NSCLC patients following platinum-based chemoradiotherapy. Thus, re-administration of platinum agents may be a promising treatment for unresectable stage III NSCLC treated with platinum-based chemoradiotherapy.

Sections du résumé

BACKGROUND BACKGROUND
Platinum-based chemoradiotherapy is the standard treatment for unresectable stage III non-small-cell lung cancer (NSCLC). However, few studies have evaluated the efficacy of subsequent chemotherapy for relapsed NSCLC following platinum-based chemoradiotherapy. This study aimed to evaluate the efficacy of platinum-doublet chemotherapy as a second-line treatment for patients with unresectable stage III NSCLC.
METHODS METHODS
We retrospectively evaluated patients with unresectable stage III NSCLC treated with cytotoxic chemotherapy following platinum-based chemoradiotherapy who were registered in a nationwide registry NSCLC database. Patients were divided into the platinum-doublet chemotherapy (platinum) group and single-agent chemotherapy (non-platinum) group based on the type of second-line chemotherapy.
RESULTS RESULTS
The platinum group (n = 119) showed significantly better overall survival (OS) than the non-platinum group (n = 201) (median OS: 21.5 vs. 10.5 months, hazard ratio [HR]: 0.54, 95% confidence interval [CI]: 0.40-0.73, p < 0.001). OS from the beginning of chemoradiotherapy was also significantly better in the platinum group than in the non-platinum group (median OS: 34.9 vs. 21.8 months, HR: 0.58, 95% CI: 0.43-0.79, p = 0.001). In the multivariate analysis, platinum-doublet chemotherapy as second-line therapy, female sex, clinical stage IIIA, and duration of ≥ 8.6 months from the beginning of first-line therapy to the beginning of second-line therapy were associated with significantly better OS.
CONCLUSION CONCLUSIONS
Platinum-doublet chemotherapy as a second-line therapy may prolong survival in unresectable stage III NSCLC patients following platinum-based chemoradiotherapy. Thus, re-administration of platinum agents may be a promising treatment for unresectable stage III NSCLC treated with platinum-based chemoradiotherapy.

Identifiants

DOI: 10.1186/s12885-022-09441-3 PMID: 35351059 PMC: PMC8962203
pubmed: 35351059
doi: 10.1186/s12885-022-09441-3
pii: 10.1186/s12885-022-09441-3
pmc: PMC8962203
doi:

Substances chimiques

Platinum 49DFR088MY

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

342

Informations de copyright

© 2022. The Author(s).

Références

N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
J Thorac Oncol. 2007 Aug;2(8):706-14
pubmed: 17762336
Lancet Oncol. 2016 Aug;17(8):1147-1157
pubmed: 27312053
Int J Clin Oncol. 2004 Oct;9(5):378-82
pubmed: 15549588
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
J Clin Oncol. 2016 Mar 20;34(9):953-62
pubmed: 26811519
World J Clin Oncol. 2017 Feb 10;8(1):1-20
pubmed: 28246582
Springerplus. 2015 Mar 31;4:152
pubmed: 25897409
Lancet. 2003 Jun 21;361(9375):2099-106
pubmed: 12826431
Eur J Cancer. 2014 Sep;50(13):2211-8
pubmed: 24981975
J Exp Clin Cancer Res. 2010 Apr 27;29:38
pubmed: 20423465
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
J Clin Oncol. 2000 Jun;18(12):2354-62
pubmed: 10856094
Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56
pubmed: 29232464
Lung Cancer. 2007 Oct;58(1):73-9
pubmed: 17548127
Cancer Med. 2020 Sep;9(18):6597-6608
pubmed: 32730697
Cancer Med. 2013 Dec;2(6):916-24
pubmed: 24403265
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Cancer Sci. 2020 May;111(5):1685-1691
pubmed: 32103551
Cancer Chemother Pharmacol. 2011 Dec;68(6):1405-12
pubmed: 21468755
Oncol Rep. 1999 Jul-Aug;6(4):797-800
pubmed: 10373659
J Clin Oncol. 2000 May;18(10):2095-103
pubmed: 10811675
Lung Cancer. 2013 Sep;81(3):337-342
pubmed: 23891507
Lancet. 2014 Aug 23;384(9944):665-73
pubmed: 24933332
J Clin Oncol. 2015 Feb 20;33(6):532-3
pubmed: 25559800
J Clin Oncol. 2010 May 1;28(13):2181-90
pubmed: 20351327
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Lung Cancer. 2010 Oct;70(1):71-6
pubmed: 20096475
Lancet Oncol. 2014 Feb;15(2):143-55
pubmed: 24411639
Lancet Oncol. 2019 Jul;20(7):924-937
pubmed: 31122901
BMC Cancer. 2010 Nov 19;10:633
pubmed: 21092076
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Anticancer Res. 2005 May-Jun;25(3c):2555-9
pubmed: 16080492
Clin Transl Oncol. 2020 Jan;22(1):21-36
pubmed: 31172444
Int J Gynecol Cancer. 2011 May;21(4):771-5
pubmed: 21543939
J Clin Oncol. 2012 Dec 20;30(36):4501-7
pubmed: 23109689
J Clin Oncol. 2004 May 1;22(9):1589-97
pubmed: 15117980
J Clin Oncol. 2006 Oct 10;24(29):4699-707
pubmed: 16966687
Tumour Biol. 2016 Jul;37(7):8901-7
pubmed: 26753955
Med Oncol. 2011 Mar;28(1):300-6
pubmed: 20049560

Auteurs

Eriko Miyawaki (E)

Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.

Hirotsugu Kenmotsu (H)

Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. h.kenmotsu@scchr.jp.

Yasushi Shintani (Y)

Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Ikuo Sekine (I)

Department of Medical Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, 305-8576, Japan.

Takehito Shukuya (T)

Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, 113-8431, Japan.

Koichi Takayama (K)

Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan.

Akira Inoue (A)

Department of Palliative Medicine, Tohoku University School of Medicine, Miyagi, 980-8574, Japan.

Isamu Okamoto (I)

Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.

Katsuyuki Kiura (K)

Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, 700-8558, Japan.

Kazuhisa Takahashi (K)

Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, 113-8431, Japan.

Nobuyuki Yamamoto (N)

Internal Medicine III, Wakayama Medical University, Wakayama, 641-8509, Japan.

Tomoya Kawaguchi (T)

Department of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, 545-8586, Japan.

Etsuo Miyaoka (E)

Department of Mathematics, Tokyo University of Science, Tokyo, 162-8601, Japan.

Ichiro Yoshino (I)

Department of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, 260-8677, Japan.

Hiroshi Date (H)

Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Efficacy of platinum agents for stage III...
questionsmedicales.fr › Thérapeutique › Radiothérapie › Chimioradiothérapie › Efficacy of platinum agents for stage III...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Efficacy of platinum agents for stage III...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Efficacy of platinum agents for stage III...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Efficacy of platinum agents for stage III...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Platine › Efficacy of platinum agents for stage III...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Efficacy of platinum agents for stage III...